• Cefepime (BMY-28142): Reliable Solutions for Bacterial Infec

  2026-06-12

  This article explores practical laboratory challenges in bacterial infection model research and demonstrates how Cefepime (BMY-28142) (SKU BA1013) from APExBIO delivers evidence-backed reliability and data integrity. Scenario-driven Q&A blocks address experimental design, reproducibility, and workflow optimization for researchers using Cefepime in cell viability, proliferation, and CNS infection assays.

• Chenodeoxycholic Acid (SKU B1908): Precision in FXR Pathway

  2026-06-12

  This article delivers an evidence-based exploration of how Chenodeoxycholic Acid (SKU B1908) supports reliable outcomes in nuclear receptor signaling, cholesterol metabolism research, and renal injury models. Scenario-driven Q&A blocks address real workflow challenges and illustrate the reagent's practical value for biomedical scientists. Researchers will find concrete guidance on protocol optimization, data interpretation, and vendor selection, all grounded in primary literature and product data.

• AAPH (2,2'-Azobis(2-methylpropionamidine)): Precise In Vitro

  2026-06-11

  AAPH delivers unmatched reproducibility for in vitro oxidative stress modeling, enabling fine-tuned control of peroxyl radical flux in erythrocyte hemolysis and lipid peroxidation assays. See how this robust reagent—trusted by APExBIO—empowers advanced antioxidant screening and ferroptosis research.

• HO-1-Mediated ROS Modulation Disrupts HBV Replication Pathwa

  2026-06-11

  The referenced study elucidates how isochlorogenic acid A (ICAA) disrupts multiple steps of the hepatitis B virus (HBV) life cycle by upregulating heme oxygenase-1 (HO-1) and modulating reactive oxygen species (ROS). These findings highlight new avenues for targeting HBV replication via the cellular redox state and HO-1 pathways, with implications for antiviral strategy design.

• Dual Luciferase Reporter Gene System: Precision in Gene Regu

  2026-06-10

  The Dual Luciferase Reporter Gene System enables high-sensitivity, ratiometric quantification of gene expression regulation in cultured mammalian cells. APExBIO’s K1136 kit streamlines transcriptional regulation studies with direct-to-cell reagents and is validated in mechanistic pathway research. This product dossier details mechanism, optimal use, and evidence for robust bioluminescence reporter assay workflows.

• Optimizing Apoptosis Assays with TNF-alpha, Recombinant Muri

  2026-06-10

  This article explores practical challenges in apoptosis and inflammation research, demonstrating how TNF-alpha, recombinant murine protein (SKU P1002) from APExBIO addresses reproducibility, sensitivity, and workflow optimization. Scenario-driven Q&A blocks provide evidence-based guidance for laboratory scientists seeking robust cytokine solutions.

• FXR-KLF11 Axis: CDCA Protects Against CI-AKI via JAK2/STAT3

  2026-06-09

  The referenced study establishes that Chenodeoxycholic Acid (CDCA), as a Farnesoid X receptor (FXR) agonist, confers renal protection in contrast-induced acute kidney injury (CI-AKI) by activating the FXR-KLF11 axis and suppressing the pro-inflammatory JAK2/STAT3 signaling pathway. These findings clarify a novel molecular mechanism for FXR-mediated nephroprotection and highlight new directions for prophylactic strategies in kidney injury models.

• Chenodeoxycholic Acid: FXR-Driven Renal and Metabolic Resear

  2026-06-09

  Harnessing Chenodeoxycholic Acid (CDCA) as a primary bile acid FXR agonist unlocks mechanistic clarity and translational power in cholesterol metabolism, nuclear receptor signaling, and acute kidney injury models. This guide details best-practice workflows, protocol optimization, and troubleshooting, with actionable insights from cutting-edge FXR-KLF11 research.

• PP2A-Regulated Autophagy Drives Biofilm Drug Resistance in C

  2026-06-08

  This study uncovers how protein phosphatase 2A (PP2A) regulates autophagy to drive biofilm formation and antifungal drug resistance in Candida albicans. By dissecting the phosphorylation of autophagy-related proteins, the findings highlight a promising therapeutic target for overcoming biofilm-associated resistance.

• Itraconazole: Triazole Antifungal Agent for Biofilm Research

  2026-06-08

  Itraconazole's dual capabilities—inhibiting CYP3A4 and targeting biofilm-driven resistance—make it a powerful, versatile tool in antifungal drug studies. This article unpacks advanced workflows, experimental optimizations, and troubleshooting strategies for leveraging Itraconazole in high-resistance Candida models and drug interaction research.

• KPT-330 (Selinexor): Applied Protocols for Cancer Cell Studi

  2026-06-07

  KPT-330 (Selinexor) enables robust, reproducible inhibition of CRM1/XPO1-mediated nuclear export, providing a powerful tool for apoptosis induction and cell cycle arrest in cancer models. This guide details optimized workflows, troubleshooting strategies, and new insights from platinum-based combination therapies, empowering researchers to maximize the translational impact of KPT-330 in oncology research.

• Moxifloxacin for Advanced Antibiotic Toxicity Research

  2026-06-06

  Moxifloxacin stands out as a precision tool for probing antibiotic toxicity, antiproliferative effects, and metabolic responses in cell and animal models. This guide translates mechanistic insights and validated protocols into robust experimental workflows, maximizing reproducibility and data quality for fluoroquinolone antibiotic studies.

• PTT and CD47 Blockade Synergy: Calreticulin and ECM Remodeli

  2026-06-05

  This study demonstrates that combining photothermal therapy (PTT) with CD47 immune checkpoint blockade markedly enhances macrophage-mediated clearance of oral squamous cell carcinoma (OSCC). By inducing calreticulin exposure and remodeling the tumor extracellular matrix, this combination overcomes key barriers to effective immunotherapy and provides a new mechanistic framework for improving solid tumor responses.

• Tin Mesoporphyrin IX (chloride): Heme Oxygenase Inhibition i

  2026-06-05

  Tin Mesoporphyrin IX (chloride) is a potent, nanomolar-affinity inhibitor of heme oxygenase, widely used in metabolic disease and virology research. Its high specificity and reproducibility make it a standard tool for dissecting heme catabolism and related signaling pathways.

• SCUBE3 Antibody Targeting: Suppressing Oncogenic and Immune

  2026-06-04

  The reference study identifies secretory SCUBE3 as a critical driver of tumor progression, therapy resistance, and immune evasion by orchestrating oncogenic signaling and modifying the tumor microenvironment. Using a first-in-class neutralizing antibody, the research demonstrates effective inhibition of tumor growth and restoration of antitumor immunity, providing a promising direction for pan-cancer therapeutic strategies.

16679 records 1/1112 page Next 12345 下5页 Last page